Gyre Therapeutics (GYRE) Financials

$8.68 -2.53 (-22.57%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$8.98 +0.30 (+3.50%)

As of 05/23/2025 07:58 PM Eastern

Annual Income Statements for Gyre Therapeutics

This table shows Gyre Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Income / (Loss) Attributable to Common Shareholders	12	-93	2.30
Consolidated Net Income / (Loss)	18	-85	4.31
Net Income / (Loss) Continuing Operations	18	-85	4.31
Total Pre-Tax Income	23	-77	9.41
Total Operating Income	16	-67	9.20
Total Gross Profit	102	109	97
Total Revenue	106	113	102
Operating Revenue	106	113	102
Total Cost of Revenue	3.88	4.64	4.79
Operating Cost of Revenue	3.88	4.64	4.79
Total Operating Expenses	86	176	88
Selling, General & Admin Expense	16	15	17
Marketing Expense	58	61	54
Research & Development Expense	12	97	17
Other Operating Expenses / (Income)	0.00	2.71	-
Other Special Charges / (Income)	0.07	0.63	0.00
Total Other Income / (Expense), net	7.06	-9.74	0.21
Interest Expense	-1.55	-1.04	-0.73
Other Income / (Expense), net	5.51	-11	-0.52
Income Tax Expense	5.32	8.52	5.10
Net Income / (Loss) Attributable to Noncontrolling Interest	5.81	7.45	2.01
Basic Earnings per Share	$0.14	($1.41)	$0.04
Weighted Average Basic Shares Outstanding	85.09M	65.83M	63.59M
Diluted Earnings per Share	$0.05	($1.41)	$0.03
Weighted Average Diluted Shares Outstanding	102.29M	65.83M	75.69M
Weighted Average Basic & Diluted Shares Outstanding	93.61M	85.42M	37.76M

This table shows Gyre Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-0.10	1.12	3.53	7.53	-101	3.98	1.85	2.24	-30	-4.88
Consolidated Net Income / (Loss)	0.57	2.86	4.54	9.94	-101	7.51	3.77	4.22	-28	-4.88
Net Income / (Loss) Continuing Operations	0.57	2.86	4.54	9.94	-101	7.51	3.77	4.22	-28	-4.88
Total Pre-Tax Income	0.77	3.93	6.04	12	-100	11	5.85	6.27	-23	-4.88
Total Operating Income	0.60	4.23	3.26	8.07	-92	13	4.97	6.66	-22	-5.17
Total Gross Profit	27	25	24	26	26	31	28	24	98	0.00
Total Revenue	28	25	25	27	27	32	29	25	101	0.00
Operating Revenue	28	25	25	27	27	32	29	25	101	0.00
Total Cost of Revenue	1.18	0.96	0.77	0.98	1.25	1.18	1.08	1.13	4.00	0.00
Operating Cost of Revenue	1.18	0.96	0.77	0.98	1.25	1.18	1.08	1.13	4.00	0.00
Total Operating Expenses	26	20	21	18	117	19	23	17	120	5.17
Selling, General & Admin Expense	5.46	3.82	3.42	3.40	10	1.16	1.71	1.74	4.17	4.36
Marketing Expense	17	14	14	13	16	14	18	13	-	-
Research & Development Expense	3.71	2.78	3.36	2.18	88	3.01	3.57	2.64	4.31	0.80
Total Other Income / (Expense), net	0.11	-0.30	2.84	4.41	-9.17	-1.05	0.88	-0.39	-0.34	0.28
Interest Expense	-0.35	-0.52	-0.35	-0.33	-0.33	-0.28	-0.25	-0.18	-0.18	-0.28
Other Income / (Expense), net	-0.24	-0.83	2.49	4.08	-9.50	-1.33	0.63	-0.58	-	-
Income Tax Expense	0.20	1.07	1.50	2.55	0.70	3.68	2.08	2.05	5.10	0.00
Net Income / (Loss) Attributable to Noncontrolling Interest	0.67	1.73	1.01	2.40	0.03	3.53	1.92	1.97	-	-
Weighted Average Basic Shares Outstanding	85.09M	85.64M	85.50M	83.27M	65.83M	63.59M	63.59M	63.59M	63.59M	31.48M
Weighted Average Diluted Shares Outstanding	102.29M	102.64M	104.33M	102.59M	65.83M	78.90M	78.90M	78.92M	75.69M	31.48M
Weighted Average Basic & Diluted Shares Outstanding	93.61M	93.52M	93.42M	85.51M	85.42M	37.98M	37.97M	37.76M	37.76M	31.49M

This table details how cash moves in and out of Gyre Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Change in Cash & Equivalents	-22	8.33	-5.03
Net Cash From Operating Activities	-3.64	26	11
Net Cash From Continuing Operating Activities	-3.64	26	11
Net Income / (Loss) Continuing Operations	18	-85	4.31
Consolidated Net Income / (Loss)	18	-85	4.31
Depreciation Expense	1.55	1.07	1.09
Amortization Expense	0.04	0.04	0.04
Non-Cash Adjustments To Reconcile Net Income	-11	105	14
Changes in Operating Assets and Liabilities, net	-13	4.76	-8.64
Net Cash From Investing Activities	-20	-20	-14
Net Cash From Continuing Investing Activities	-20	-20	-14
Purchase of Property, Plant & Equipment	-2.32	-8.52	-4.99
Acquisitions	-2.50	-1.19	-1.35
Sale of Property, Plant & Equipment	0.40	0.66	0.00
Divestitures	0.00	5.59	0.00
Other Investing Activities, net	-15	-16	-7.48
Net Cash From Financing Activities	2.10	2.50	0.00
Net Cash From Continuing Financing Activities	2.10	2.50	0.00
Repayment of Debt	0.00	-	-
Repurchase of Preferred Equity	0.00	2.50	0.00
Issuance of Common Equity	0.77	0.00	-
Other Financing Activities, net	1.33	0.00	-
Effect of Exchange Rate Changes	-0.27	-0.30	-1.89
Cash Income Taxes Paid	8.52	6.35	6.31

This table details how cash moves in and out of Gyre Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-4.05	-0.23	-14	-3.72	7.43	2.35	-4.42	2.97	16	-52
Net Cash From Operating Activities	-2.76	1.73	-5.49	2.88	3.36	7.58	4.53	10	42	-7.28
Net Cash From Continuing Operating Activities	-2.76	1.73	-5.49	2.88	3.36	7.58	4.53	10	42	-7.28
Net Income / (Loss) Continuing Operations	0.57	2.86	4.54	9.94	-101	7.51	3.77	4.22	-28	-4.88
Consolidated Net Income / (Loss)	0.57	2.86	4.54	9.94	-101	7.51	3.77	4.22	-28	-4.88
Depreciation Expense	0.46	0.45	0.23	0.42	0.30	0.19	0.31	0.28	0.87	0.04
Amortization Expense	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	-	-
Non-Cash Adjustments To Reconcile Net Income	-3.61	0.15	-2.67	-4.41	104	0.69	0.55	0.29	70	0.33
Changes in Operating Assets and Liabilities, net	-0.18	-1.73	-7.60	-3.06	0.06	-0.82	-0.10	5.63	-0.43	-2.77
Net Cash From Investing Activities	-2.00	-2.39	-8.27	-7.22	1.34	-5.40	-8.05	-7.65	-69	-
Net Cash From Continuing Investing Activities	-2.00	-2.39	-8.27	-7.22	1.34	-5.40	-8.05	-7.65	-69	-
Purchase of Property, Plant & Equipment	0.07	-0.69	-1.46	-0.23	-2.32	-1.97	-2.48	-1.74	-	-
Acquisitions	-2.50	-0.00	-	0.00	-1.13	-0.00	-0.00	-0.07	-	-
Sale of Property, Plant & Equipment	0.14	-0.01	0.22	0.05	0.17	0.36	0.13	0.00	-0.45	-
Other Investing Activities, net	0.29	-1.69	-7.04	-7.04	-1.97	-2.79	-5.71	-5.84	-60	-
Net Cash From Financing Activities	0.96	0.32	0.16	0.66	2.50	-	-	0.00	45	-45
Net Cash From Continuing Financing Activities	0.96	0.32	0.16	0.66	2.50	-	-	0.00	45	-45
Other Financing Activities, net	0.02	0.37	0.28	0.66	-	-	-	0.00	-	0.00
Cash Income Taxes Paid	0.76	0.54	5.78	1.44	0.96	1.38	3.54	0.46	-	-

This table presents Gyre Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Total Assets	125	117	85
Total Current Assets	65	57	50
Cash & Equivalents	12	34	25
Short-Term Investments	15	0.00	-
Note & Lease Receivable	9.33	0.39	17
Accounts Receivable	20	16	0.00
Inventories, net	6.34	4.28	6.12
Prepaid Expenses	1.19	1.55	0.38
Other Current Assets	1.44	1.05	0.84
Plant, Property, & Equipment, net	24	23	18
Total Noncurrent Assets	37	36	17
Noncurrent Note & Lease Receivables	0.00	4.72	0.00
Intangible Assets	0.27	0.21	0.30
Noncurrent Deferred & Refundable Income Taxes	5.62	4.70	4.08
Other Noncurrent Operating Assets	31	26	13
Total Liabilities & Shareholders' Equity	125	117	85
Total Liabilities	27	38	13
Total Current Liabilities	20	20	12
Accounts Payable	0.11	0.36	0.12
Accrued Expenses	11	12	9.26
Current Deferred Revenue	0.00	0.00	0.15
Current Deferred & Payable Income Tax Liabilities	2.83	5.05	2.10
Other Current Liabilities	5.96	2.70	0.61
Total Noncurrent Liabilities	7.49	18	0.29
Noncurrent Deferred Revenue	0.93	0.21	0.12
Other Noncurrent Operating Liabilities	6.56	18	0.18
Commitments & Contingencies	0.00	0.00	0.00
Redeemable Noncontrolling Interest	0.00	65	0.00
Total Equity & Noncontrolling Interests	98	14	72
Total Preferred & Common Equity	63	-16	43
Total Common Equity	63	-16	43
Common Stock	136	68	33
Retained Earnings	-73	-86	7.40
Accumulated Other Comprehensive Income / (Loss)	-2.60	-1.64	-0.39
Other Equity Adjustments	3.10	3.10	2.66
Noncontrolling Interest	35	30	30

This table presents Gyre Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	125	121	122	9.96	12	19	31
Total Current Assets	55	54	63	5.13	7.62	14	30
Cash & Equivalents	16	16	30	2.23	6.92	8.10	23
Short-Term Investments	9.23	9.00	7.57	-	-	-	0.00
Note & Lease Receivable	19	19	15	-	-	-	-
Accounts Receivable	1.29	1.29	1.29	1.20	0.00	5.00	5.00
Inventories, net	6.38	5.64	4.94	-	-	-	-
Prepaid Expenses	1.05	1.15	1.79	1.70	0.70	0.92	2.16
Other Current Assets	1.51	1.72	1.90	-	-	-	-
Plant, Property, & Equipment, net	24	24	24	0.00	0.00	0.00	0.12
Total Noncurrent Assets	46	44	36	4.83	4.77	4.74	0.65
Noncurrent Note & Lease Receivables	4.90	4.84	4.78	4.66	4.61	4.55	-
Intangible Assets	0.18	0.19	0.20	-	-	-	-
Noncurrent Deferred & Refundable Income Taxes	5.16	5.08	5.00	-	-	-	-
Other Noncurrent Operating Assets	36	34	26	0.17	0.17	0.19	0.65
Total Liabilities & Shareholders' Equity	125	121	122	9.96	12	19	31
Total Liabilities	27	28	33	6.45	7.40	11	1.64
Total Current Liabilities	15	16	19	1.78	2.79	6.84	1.64
Accounts Payable	0.30	0.27	0.33	0.16	0.01	0.02	0.04
Accrued Expenses	9.55	11	11	0.92	2.07	0.74	0.18
Current Deferred Revenue	0.04	0.06	0.04	-	-	-	0.00
Current Deferred & Payable Income Tax Liabilities	2.84	2.26	6.47	-	-	-	-
Other Current Liabilities	1.98	2.47	1.88	0.00	0.00	5.00	0.38
Total Noncurrent Liabilities	12	12	14	4.66	4.61	4.55	0.00
Noncurrent Deferred Revenue	0.19	0.19	0.20	-	-	-	-
Other Noncurrent Operating Liabilities	12	12	14	4.66	4.61	4.55	0.00
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Redeemable Noncontrolling Interest	0.00	0.00	0.00	0.00	33	33	-
Total Equity & Noncontrolling Interests	98	93	89	3.52	-28	-26	29
Total Preferred & Common Equity	63	60	57	3.52	-28	-26	29
Total Common Equity	63	60	57	-30	-28	-26	29
Common Stock	134	134	133	385	385	385	400
Retained Earnings	-73	-74	-78	-415	-413	-411	-370
Accumulated Other Comprehensive Income / (Loss)	-0.95	-2.01	-1.74	-	-	-	-
Other Equity Adjustments	3.10	3.10	3.10	-	-	-	-
Noncontrolling Interest	35	33	32	-	-	-	-

This table displays calculated financial ratios and metrics derived from Gyre Therapeutics' official financial filings.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Growth Metrics	-	-	-
Revenue Growth	-6.78%	10.91%	1,293.98%
EBITDA Growth	130.25%	-883.44%	111.20%
EBIT Growth	127.78%	-998.10%	109.88%
NOPAT Growth	126.48%	-1,215.66%	106.86%
Net Income Growth	120.94%	-2,081.46%	104.91%
EPS Growth	103.55%	-4,800.00%	101.05%
Operating Cash Flow Growth	-114.06%	142.50%	112.75%
Free Cash Flow Firm Growth	68.20%	7.41%	21.12%
Invested Capital Growth	59.53%	-4.42%	916.42%
Revenue Q/Q Growth	0.69%	-39.59%	3,062.96%
EBITDA Q/Q Growth	128.68%	-2,244.91%	-16.00%
EBIT Q/Q Growth	126.26%	-4,116.94%	-23.47%
NOPAT Q/Q Growth	123.40%	-0.25%	-62.84%
Net Income Q/Q Growth	121.40%	-589.30%	-63.70%
EPS Q/Q Growth	103.42%	-58.43%	-92.11%
Operating Cash Flow Q/Q Growth	-246.99%	-60.06%	121.66%
Free Cash Flow Firm Q/Q Growth	88.59%	-7.24%	-3,916.64%
Invested Capital Q/Q Growth	-2.25%	3,388.36%	648.48%
Profitability Metrics	-	-	-
Gross Margin	96.33%	95.91%	95.31%
EBITDA Margin	21.99%	-67.78%	9.60%
Operating Margin	15.28%	-59.26%	9.00%
EBIT Margin	20.49%	-68.76%	8.49%
Profit (Net Income) Margin	16.92%	-75.35%	4.22%
Tax Burden Percent	77.09%	111.06%	45.84%
Interest Burden Percent	107.14%	98.66%	108.36%
Effective Tax Rate	22.91%	0.00%	54.16%
Return on Invested Capital (ROIC)	21.35%	-102.30%	20.44%
ROIC Less NNEP Spread (ROIC-NNEP)	3.28%	28.64%	20.17%
Return on Net Nonoperating Assets (RNNOA)	-1.12%	-11.15%	-12.82%
Return on Equity (ROE)	20.24%	-113.45%	7.61%
Cash Return on Invested Capital (CROIC)	-24.52%	-97.78%	-103.28%
Operating Return on Assets (OROA)	17.91%	-77.51%	12.37%
Return on Assets (ROA)	14.80%	-84.93%	6.14%
Return on Common Equity (ROCE)	5.43%	-20.10%	5.62%
Return on Equity Simple (ROE_SIMPLE)	28.27%	540.06%	10.15%
Net Operating Profit after Tax (NOPAT)	12	-47	4.22
NOPAT Margin	11.78%	-41.48%	4.12%
Net Nonoperating Expense Percent (NNEP)	18.07%	-130.94%	0.27%
Return On Investment Capital (ROIC_SIMPLE)	12.66%	-337.38%	-
Cost of Revenue to Revenue	3.67%	4.09%	4.69%
SG&A Expenses to Revenue	15.23%	12.92%	16.98%
R&D to Revenue	11.37%	85.40%	16.31%
Operating Expenses to Revenue	81.04%	155.17%	86.32%
Earnings before Interest and Taxes (EBIT)	22	-78	8.69
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	23	-77	9.82
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	17.87	0.00	0.39
Price to Tangible Book Value (P/TBV)	17.95	0.00	0.39
Price to Revenue (P/Rev)	10.70	8.60	0.16
Price to Earnings (P/E)	93.64	0.00	7.22
Dividend Yield	0.00%	0.00%	271.09%
Earnings Yield	1.07%	0.00%	13.86%
Enterprise Value to Invested Capital (EV/IC)	15.89	23.05	0.45
Enterprise Value to Revenue (EV/Rev)	10.78	9.14	0.21
Enterprise Value to EBITDA (EV/EBITDA)	49.01	0.00	2.15
Enterprise Value to EBIT (EV/EBIT)	52.61	0.00	2.43
Enterprise Value to NOPAT (EV/NOPAT)	91.50	0.00	5.01
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	40.03	1.98
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00
Financial Leverage	-0.34	-0.39	-0.64
Leverage Ratio	1.37	1.34	1.24
Compound Leverage Factor	1.47	1.32	1.34
Debt to Total Capital	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	35.65%	120.17%	41.12%
Common Equity to Total Capital	64.35%	-20.17%	58.88%
Debt to EBITDA	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00
Altman Z-Score	26.17	13.50	2.99
Noncontrolling Interest Sharing Ratio	73.15%	82.29%	26.21%
Liquidity Ratios	-	-	-
Current Ratio	3.32	2.85	4.06
Quick Ratio	2.86	2.51	3.46
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-14	-45	-49
Operating Cash Flow to CapEx	-190.23%	329.71%	214.18%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00
Efficiency Ratios	-	-	-
Asset Turnover	0.87	1.13	1.46
Accounts Receivable Turnover	5.83	0.00	0.00
Inventory Turnover	0.73	0.89	0.00
Fixed Asset Turnover	4.48	5.53	10.95
Accounts Payable Turnover	16.78	19.44	1.47
Days Sales Outstanding (DSO)	62.59	0.00	0.00
Days Inventory Outstanding (DIO)	498.91	409.52	0.00
Days Payable Outstanding (DPO)	21.76	18.78	249.06
Cash Conversion Cycle (CCC)	539.75	390.75	-249.06
Capital & Investment Metrics	-	-	-
Invested Capital	72	45	47
Invested Capital Turnover	1.81	2.47	4.96
Increase / (Decrease) in Invested Capital	27	-2.08	53
Enterprise Value (EV)	1,140	1,036	21
Market Capitalization	1,132	976	17
Book Value per Share	$0.68	($0.42)	$1.35
Tangible Book Value per Share	$0.67	($0.42)	$1.34
Total Capital	98	78	72
Total Debt	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00
Net Debt	-27	-34	-25
Capital Expenditures (CapEx)	1.91	7.85	4.99
Debt-free, Cash-free Net Working Capital (DFCFNWC)	19	3.67	12
Debt-free Net Working Capital (DFNWC)	45	37	37
Net Working Capital (NWC)	45	37	37
Net Nonoperating Expense (NNE)	-5.44	38	-0.10
Net Nonoperating Obligations (NNO)	-27	-34	-25
Total Depreciation and Amortization (D&A)	1.59	1.11	1.13
Debt-free, Cash-free Net Working Capital to Revenue	17.59%	3.23%	11.96%
Debt-free Net Working Capital to Revenue	42.81%	32.77%	36.57%
Net Working Capital to Revenue	42.81%	32.77%	36.57%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	$0.14	($1.41)	($0.26)
Adjusted Weighted Average Basic Shares Outstanding	85.09M	65.83M	31.55M
Adjusted Diluted Earnings per Share	$0.05	($1.41)	($0.26)
Adjusted Weighted Average Diluted Shares Outstanding	102.29M	65.83M	31.55M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	93.61M	85.42M	37.76M
Normalized Net Operating Profit after Tax (NOPAT)	13	-47	6.44
Normalized NOPAT Margin	11.83%	-41.09%	6.30%
Pre Tax Income Margin	21.95%	-67.84%	9.20%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Gyre Therapeutics' official financial filings.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	2.67%	-20.45%	-13.99%	8.99%	-73.25%	0.00%	0.00%	3,039.92%	4,059.67%	-100.00%
EBITDA Growth	100.82%	-66.81%	1.18%	97.36%	-366.92%	326.94%	-88.52%	143.69%	-6.91%	79.61%
EBIT Growth	100.35%	-70.20%	2.68%	99.66%	-350.27%	321.27%	-89.13%	141.41%	-10.57%	79.52%
NOPAT Growth	100.69%	-64.10%	-23.43%	43.37%	-307.98%	336.93%	-93.78%	143.55%	-10.57%	79.52%
Net Income Growth	100.56%	-61.97%	20.37%	135.59%	-261.95%	253.77%	-92.70%	129.01%	-37.23%	80.65%
EPS Growth	0.00%	-80.00%	-50.00%	0.00%	-52.53%	131.25%	-98.78%	106.52%	-54.69%	80.00%
Operating Cash Flow Growth	-182.08%	-77.24%	-221.18%	-72.31%	-92.06%	204.19%	136.87%	186.45%	339.30%	66.31%
Free Cash Flow Firm Growth	57.58%	-608.83%	-869.62%	-1,723.13%	9.43%	199.06%	-81.08%	54.13%	-379.70%	42.62%
Invested Capital Growth	59.53%	5,592.94%	3,639.73%	7,020.46%	-4.42%	-79.49%	-152.56%	90.39%	916.42%	265.74%
Revenue Q/Q Growth	9.35%	1.04%	-7.17%	-54.09%	-15.27%	9.25%	17.64%	-75.44%	0.00%	0.00%
EBITDA Q/Q Growth	-78.53%	-35.55%	-52.37%	116.51%	-966.69%	96.47%	-7.09%	129.51%	-321.24%	-109.93%
EBIT Q/Q Growth	-89.49%	-40.78%	-52.66%	115.73%	-984.70%	104.02%	-7.95%	127.10%	-334.77%	-110.03%
NOPAT Q/Q Growth	-85.70%	25.41%	-61.82%	111.88%	-848.64%	167.47%	-28.52%	128.50%	-334.77%	-107.02%
Net Income Q/Q Growth	-80.08%	-37.06%	-54.32%	110.81%	-1,444.57%	99.20%	-10.60%	115.12%	-471.21%	-109.46%
EPS Q/Q Growth	0.00%	0.00%	-66.67%	102.11%	-3,120.00%	150.00%	-33.33%	103.03%	-518.75%	-109.76%
Operating Cash Flow Q/Q Growth	-259.79%	131.42%	-290.46%	-92.37%	-55.68%	67.26%	-56.48%	-75.37%	681.26%	40.81%
Free Cash Flow Firm Q/Q Growth	61.86%	-1.91%	-48.07%	12.03%	-557.58%	54.15%	450.75%	96.34%	-400.44%	-129.45%
Invested Capital Q/Q Growth	-2.25%	7.53%	32.73%	14.35%	3,388.36%	166.86%	-159.49%	-101.58%	648.48%	71.35%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	95.78%	96.24%	96.95%	96.40%	95.40%	96.30%	96.33%	95.49%	96.06%	0.00%
EBITDA Margin	2.97%	15.15%	23.75%	46.29%	-371.38%	36.31%	20.19%	25.56%	-21.27%	0.00%
Operating Margin	2.14%	16.61%	12.93%	29.70%	-337.53%	39.84%	16.96%	26.73%	-22.13%	0.00%
EBIT Margin	1.28%	13.37%	22.81%	44.73%	-372.51%	35.68%	19.10%	24.42%	-22.13%	0.00%
Profit (Net Income) Margin	2.04%	11.21%	17.99%	36.56%	-371.95%	23.44%	12.85%	16.91%	-27.49%	0.00%
Tax Burden Percent	73.70%	72.67%	75.19%	79.60%	100.70%	67.13%	64.40%	67.25%	122.36%	100.00%
Interest Burden Percent	215.64%	115.35%	104.90%	102.70%	99.16%	97.87%	104.48%	103.02%	101.51%	94.54%
Effective Tax Rate	26.30%	27.33%	24.81%	20.40%	0.00%	32.87%	35.60%	32.75%	0.00%	0.00%
Return on Invested Capital (ROIC)	2.86%	33.95%	32.72%	107.96%	-582.67%	1,326.02%	1,955.34%	0.00%	-76.77%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	2.43%	35.57%	19.70%	92.51%	-457.13%	1,334.38%	1,953.96%	0.00%	-42.96%	0.00%
Return on Net Nonoperating Assets (RNNOA)	-0.83%	-9.53%	-6.42%	-43.74%	178.02%	-1,027.11%	-1,913.52%	0.00%	27.31%	0.00%
Return on Equity (ROE)	2.03%	24.43%	26.31%	64.22%	-404.65%	298.91%	41.82%	133.95%	-49.46%	0.00%
Cash Return on Invested Capital (CROIC)	-24.52%	-335.71%	-172.10%	-191.05%	-97.78%	-1,107.71%	0.00%	0.00%	-103.28%	20.25%
Operating Return on Assets (OROA)	1.12%	20.77%	38.18%	73.52%	-419.90%	326.95%	62.14%	104.59%	-32.24%	0.00%
Return on Assets (ROA)	1.78%	17.41%	30.11%	60.10%	-419.27%	214.80%	41.81%	72.46%	-40.05%	0.00%
Return on Common Equity (ROCE)	0.55%	8.00%	8.57%	20.50%	-71.68%	-3.79%	25.25%	4.40%	-36.50%	0.00%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-132.40%	-130.89%	-140.82%	0.00%	-352.60%	87.57%	-88.88%	0.00%	40.45%
Net Operating Profit after Tax (NOPAT)	0.44	3.08	2.45	6.42	-64	8.57	3.20	4.48	-16	-3.62
NOPAT Margin	1.58%	12.07%	9.72%	23.64%	-236.27%	26.74%	10.92%	17.97%	-15.49%	0.00%
Net Nonoperating Expense Percent (NNEP)	0.43%	-1.61%	13.02%	15.45%	-125.54%	-8.36%	1.38%	-1.23%	-33.81%	-2.89%
Return On Investment Capital (ROIC_SIMPLE)	0.45%	-	-	-	-459.84%	-	-	-	-	-
Cost of Revenue to Revenue	4.22%	3.76%	3.05%	3.60%	4.60%	3.70%	3.67%	4.51%	3.94%	0.00%
SG&A Expenses to Revenue	19.60%	15.00%	13.57%	12.51%	37.04%	3.61%	5.83%	6.98%	4.11%	0.00%
R&D to Revenue	13.32%	10.89%	13.30%	8.03%	322.94%	9.39%	12.17%	10.57%	4.25%	0.00%
Operating Expenses to Revenue	93.39%	79.63%	84.29%	66.69%	430.99%	58.11%	79.37%	68.76%	118.20%	0.00%
Earnings before Interest and Taxes (EBIT)	0.36	3.41	5.75	12	-101	11	5.60	6.09	-22	-5.17
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	0.83	3.86	5.99	13	-101	12	5.92	6.37	-22	-5.13
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	17.87	18.54	16.90	26.36	0.00	0.00	0.00	0.00	0.39	0.54
Price to Tangible Book Value (P/TBV)	17.95	18.60	16.96	26.45	0.00	0.00	0.00	0.00	0.39	0.54
Price to Revenue (P/Rev)	10.70	11.15	9.14	12.91	8.60	0.10	0.09	0.06	0.16	4.91
Price to Earnings (P/E)	93.64	0.00	0.00	0.00	0.00	0.00	0.00	0.41	7.22	1.34
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	406.71%	690.82%	271.09%	283.73%
Earnings Yield	1.07%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	244.13%	13.86%	74.90%
Enterprise Value to Invested Capital (EV/IC)	15.89	16.10	15.06	28.94	23.05	38.32	0.00	0.00	0.45	0.00
Enterprise Value to Revenue (EV/Rev)	10.78	11.25	9.21	12.86	9.14	0.26	0.25	0.26	0.21	0.00
Enterprise Value to EBITDA (EV/EBITDA)	49.01	0.00	0.00	0.00	0.00	13.78	0.00	1.04	2.15	0.00
Enterprise Value to EBIT (EV/EBIT)	52.61	0.00	0.00	0.00	0.00	25.44	0.00	1.08	2.43	0.00
Enterprise Value to NOPAT (EV/NOPAT)	91.50	0.00	0.00	0.00	0.00	0.00	0.00	1.42	5.01	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	477.09	123.37	81.05	40.03	0.76	0.79	1.00	1.98	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.02	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.34	-0.27	-0.33	-0.47	-0.39	-0.77	-0.98	-1.25	-0.64	-0.97
Leverage Ratio	1.37	1.33	1.36	1.46	1.34	1.25	1.14	1.71	1.24	1.22
Compound Leverage Factor	2.95	1.53	1.42	1.50	1.32	1.22	1.19	1.77	1.26	1.15
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	947.09%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	35.65%	35.84%	35.35%	36.20%	120.17%	0.00%	666.85%	452.81%	41.12%	0.00%
Common Equity to Total Capital	64.35%	64.16%	64.65%	63.80%	-20.17%	-847.09%	-566.85%	-352.81%	58.88%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	25.61	26.75	22.78	27.76	12.84	-33.53	-31.07	-21.98	1.78	-10.27
Noncontrolling Interest Sharing Ratio	73.15%	67.26%	67.42%	68.08%	82.29%	101.27%	39.63%	96.72%	26.21%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	3.32	3.72	3.44	3.22	2.85	2.88	2.73	2.05	4.06	18.40
Quick Ratio	2.86	3.12	2.89	2.78	2.51	1.92	2.48	1.91	3.46	17.09
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-26	-69	-68	-46	-62	14	8.80	-2.51	-69	-14
Operating Cash Flow to CapEx	0.00%	247.28%	-443.70%	1,593.37%	155.77%	470.64%	193.47%	597.99%	9,462.64%	0.00%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.87	1.55	1.67	1.64	1.13	9.16	3.25	4.28	1.46	0.06
Accounts Receivable Turnover	5.83	84.47	0.00	36.80	0.00	60.58	0.00	45.44	0.00	1.06
Inventory Turnover	0.73	0.00	0.00	0.00	0.89	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	4.48	0.00	0.00	9.82	5.53	0.00	0.00	294.70	10.95	5.32
Accounts Payable Turnover	16.78	17.17	30.31	25.95	19.44	74.18	11.89	2.17	1.47	1.67
Days Sales Outstanding (DSO)	62.59	4.32	0.00	9.92	0.00	6.03	0.00	8.03	0.00	345.02
Days Inventory Outstanding (DIO)	498.91	0.00	0.00	0.00	409.52	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	21.76	21.26	12.04	14.06	18.78	4.92	30.69	168.31	249.06	219.03
Cash Conversion Cycle (CCC)	539.75	-16.94	-12.04	-4.15	390.75	1.10	-30.69	-160.28	-249.06	125.99
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	72	73	68	51	45	1.29	-1.93	-0.74	47	6.29
Invested Capital Turnover	1.81	2.81	3.37	4.57	2.47	49.59	179.03	-29.83	4.96	2.59
Increase / (Decrease) in Invested Capital	27	72	70	52	-2.08	-5.00	-5.60	6.99	53	10
Enterprise Value (EV)	1,140	1,182	1,028	1,488	1,036	49	40	33	21	-7.23
Market Capitalization	1,132	1,172	1,020	1,493	976	18	13	7.82	17	16
Book Value per Share	$0.68	$0.68	$0.71	$0.66	($0.42)	($0.78)	($0.75)	($0.69)	$1.35	$0.93
Tangible Book Value per Share	$0.67	$0.67	$0.70	$0.66	($0.42)	($0.78)	($0.75)	($0.69)	$1.34	$0.93
Total Capital	98	98	93	89	78	3.52	5.00	7.36	72	29
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-27	-25	-25	-37	-34	-2.23	-6.92	-8.10	-25	-23
Capital Expenditures (CapEx)	-0.20	0.70	1.24	0.18	2.16	1.61	2.34	1.74	0.45	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	19	15	13	5.89	3.67	1.12	-2.10	-0.93	12	5.51
Debt-free Net Working Capital (DFNWC)	45	40	38	43	37	3.35	4.83	7.17	37	29
Net Working Capital (NWC)	45	40	38	43	37	3.35	4.83	7.17	37	29
Net Nonoperating Expense (NNE)	-0.13	0.22	-2.09	-3.51	37	1.06	-0.57	0.26	12	1.27
Net Nonoperating Obligations (NNO)	-27	-25	-25	-37	-34	-2.23	-6.92	-8.10	-25	-23
Total Depreciation and Amortization (D&A)	0.47	0.45	0.24	0.43	0.31	0.20	0.32	0.29	0.87	0.04
Debt-free, Cash-free Net Working Capital to Revenue	17.59%	14.28%	11.51%	5.09%	3.23%	0.60%	-1.35%	-0.73%	11.96%	170.44%
Debt-free Net Working Capital to Revenue	42.81%	38.17%	34.00%	37.37%	32.77%	1.78%	3.10%	5.67%	36.57%	884.42%
Net Working Capital to Revenue	42.81%	38.17%	34.00%	37.37%	32.77%	1.78%	3.10%	5.67%	36.57%	884.42%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.01	$0.04	$0.09	($1.54)	($0.04)	($0.07)	$0.01	($0.98)	($0.16)
Adjusted Weighted Average Basic Shares Outstanding	85.09M	85.64M	85.50M	83.27M	65.83M	37.98M	37.80M	37.76M	63.59M	31.48M
Adjusted Diluted Earnings per Share	$0.00	$0.01	$0.01	$0.03	($1.51)	($0.04)	($0.07)	$0.01	($0.99)	($0.16)
Adjusted Weighted Average Diluted Shares Outstanding	102.29M	102.64M	104.33M	102.59M	65.83M	37.98M	37.80M	37.98M	75.69M	31.48M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	93.61M	93.52M	93.42M	85.51M	85.42M	37.98M	37.97M	37.76M	37.76M	31.49M
Normalized Net Operating Profit after Tax (NOPAT)	0.44	3.08	2.50	6.42	-64	8.92	3.20	4.48	24	-3.62
Normalized NOPAT Margin	1.58%	12.07%	9.93%	23.64%	-236.27%	27.84%	10.92%	17.97%	23.99%	0.00%
Pre Tax Income Margin	2.77%	15.42%	23.92%	45.93%	-369.38%	34.92%	19.96%	25.15%	-22.46%	0.00%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	378.95%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	378.95%

Frequently Asked Questions About Gyre Therapeutics' Financials

When does Gyre Therapeutics's fiscal year end?

According to the most recent income statement we have on file, Gyre Therapeutics' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Gyre Therapeutics' net income changed over the last 2 years?

Gyre Therapeutics' net income appears to be on a downward trend, with a most recent value of $17.90 million in 2024, rising from $4.31 million in 2022. The previous period was -$85.48 million in 2023. View Gyre Therapeutics' forecast to see where analysts expect Gyre Therapeutics to go next.

What is Gyre Therapeutics's operating income?

Gyre Therapeutics's total operating income in 2024 was $16.16 million, based on the following breakdown:

Total Gross Profit: $101.87 million
Total Operating Expenses: $85.71 million

How has Gyre Therapeutics revenue changed over the last 2 years?

Over the last 2 years, Gyre Therapeutics' total revenue changed from $102.29 million in 2022 to $105.76 million in 2024, a change of 3.4%.

How much debt does Gyre Therapeutics have?

Gyre Therapeutics' total liabilities were at $27.00 million at the end of 2024, a 29.1% decrease from 2023, and a 115.4% increase since 2022.

How much cash does Gyre Therapeutics have?

In the past 2 years, Gyre Therapeutics' cash and equivalents has ranged from $11.81 million in 2024 to $33.51 million in 2023, and is currently $11.81 million as of their latest financial filing in 2024.

How has Gyre Therapeutics' book value per share changed over the last 2 years?

Over the last 2 years, Gyre Therapeutics' book value per share changed from 1.35 in 2022 to 0.68 in 2024, a change of -49.9%.

Related Companies

This page (NASDAQ:GYRE) was last updated on 5/25/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Gyre Therapeutics (GYRE) Financials

Frequently Asked Questions About Gyre Therapeutics' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Gyre Therapeutics (GYRE) Financials

Annual Income Statements for Gyre Therapeutics

Quarterly Income Statements for Gyre Therapeutics

Annual Cash Flow Statements for Gyre Therapeutics

Quarterly Cash Flow Statements for Gyre Therapeutics

Annual Balance Sheets for Gyre Therapeutics

Quarterly Balance Sheets for Gyre Therapeutics

Annual Metrics And Ratios for Gyre Therapeutics

Quarterly Metrics And Ratios for Gyre Therapeutics

Frequently Asked Questions About Gyre Therapeutics' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools